Pharma, the medical industry looks set to continue in 2022: Director of OPPI


“To achieve this, these companies must strive to support, recognize, and benefit from research and development that are at high risk,” he added.

Demonstrating its global reach in times of crisis by providing 60% of the world’s population. COVID-19 DISEASES Vaccine requirements, Indian pharmaceutical companies and healthcare companies are looking to strengthen what has happened over the past two years, strengthen cooperation with the government and move forward in 2022.

Director-General of the Organization of Pharmaceutical Producers of India (OPPI) KG Ananthakrishnan PTI that it is important for these companies to continue to maximize the benefits gained during the epidemic that will enable them to play a significant role in the global pharmaceutical market.

Also read | Mandaviya is urging pharmaceutical companies to make India a manufacturing hub

“To achieve this, these companies must strive to support, recognize, and benefit from research and development that are at high risk,” he added.

“Strengthening business finance in R&D and innovative innovations through innovative technology and strict adherence to the vision that the government has achieved in India will promote environmental growth in the country,” said Ananthakrishnan.

“Harmonizing business needs to meet global standards will be crucial for the next growth in 2022 and beyond. Prices must address inflation and fair inflation,” he added.

Citing the crisis in the domestic industry, Sun Pharma (India Business) CEO Kirti Ganorkar said inflation, interest uncertainty and rising inflation and transportation costs were some of the major challenges.

“We hope that another solution will come and it will not lead to a significant increase in inflation,” he added.

However, he also said that there have been opportunities for companies to grow COVID DISEASES reputation as new antiretroviral drugs such as molnupiravir and dose-supplementing will be required.

Also read | Center works on the policy to promote research component pharma, said Mandaviya; promotes the use of drugs

“In line with our efforts to accelerate access to new COVID drugs, we will strive to provide new services to patients at a lower cost,” Ganorkar said.

Commenting on the industry innovations, Dr. Reddy’s Laboratories Co-Chairman and Managing Director GV Prasad said, “One of the things I see as having a major impact in 2022 is strengthening the partnership between government and industry, strengthening the last two years. Of the epidemic. easily and timely during COVID, “he said.

He added, “We will need a strong partnership between the government and regional agencies to ensure that we continue to support patients in India and around the world.” Shardul Amarchand Mangaldas & Co Partner Arvind Sharma also said that the medical sector in India is currently ranked third in the world in terms of US and China with a market capitalization of $ 42 billion.

“With skilled workers, technological advances and businesses affected by the epidemic, the medical sector is expected to perform well in 2022, with an expected growth rate of about 11% over the next two years and more than $ 60 billion,” he said. .

NATHEALTH Health Council President Harsh Mahajan said the Governments of the Center and the State needed to invest more money in order to be protected by primary care in order to achieve the global health goal.

“The use of digital healthcare and telemedicine became known during the epidemic and this will continue, and I see an increase in funding, to provide affordable medical care to more people,” he added.

The outbreak highlighted the weakness of the country’s health care system and the poor access to health care in 2-4 cities and rural areas, Mahajan said.

Chairman of the Medical Technology Association of India (MTaI) Pavan Choudary said the med-tech sector is looking forward to seeing the future in 2022, with a major dialogue taking place between government and industry.

“Global companies, which are the largest suppliers of med-tech funds, want to reduce barriers to price and non-payment,” he said.

Issues such as planning for data acquisition, debt repayment and reducing their workload, especially in the immediate future of India, are crucial to this process, Choudary said.

Fortis Healthcare MD and CEO Ashutosh Raghuvanshi also said the world has realized the potential of the health sector in India and by 2022, it will attract more money and support from domestic and international companies to lead operations and business growth.

“Existing agencies have seen an increase in aid in rural and rural areas. Overall, by the year 2022 looks stable, the sector is at risk and has a significant potential for financial assistance of $ 5 trillion,” he said.

Mr Ananthakrishnan also said that in 2021, the pharmaceutical industry witnessed a significant year, ranging from research and development of vaccines with several COVID drugs to digital integration and engineering.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *